Exelixis, Inc. (NASDAQ: EXEL) Stock Competitors & Peer Comparison

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while VRTX trades at $477.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas VRTX's P/E ratio is 25.35. In terms of profitability, EXEL's ROE is +0.40%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, EXEL is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check VRTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while REGN trades at $762.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas REGN's P/E ratio is 16.71. In terms of profitability, EXEL's ROE is +0.40%, compared to REGN's ROE of +0.18%. Regarding short-term risk, EXEL is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check REGN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas VRNA's P/E ratio is -102.80. In terms of profitability, EXEL's ROE is +0.40%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, EXEL is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check VRNA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ARGX trades at $853.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ARGX's P/E ratio is 78.75. In terms of profitability, EXEL's ROE is +0.40%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, EXEL is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ARGX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EXEL's ROE is +0.40%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EXEL is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check SGEN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RVMDW trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, EXEL's ROE is +0.40%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, EXEL is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RVMDW's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RVMD trades at $187.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RVMD's P/E ratio is -26.52. In terms of profitability, EXEL's ROE is +0.40%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, EXEL is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RVMD's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ONC trades at $316.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ONC's P/E ratio is 70.70. In terms of profitability, EXEL's ROE is +0.40%, compared to ONC's ROE of +0.12%. Regarding short-term risk, EXEL is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ONC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ALNY trades at $205.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ALNY's P/E ratio is 37.02. In terms of profitability, EXEL's ROE is +0.40%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, EXEL is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ALNY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ROIV trades at $33.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ROIV's P/E ratio is -34.86. In terms of profitability, EXEL's ROE is +0.40%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, EXEL is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ROIV's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while INCY trades at $119.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas INCY's P/E ratio is 16.06. In terms of profitability, EXEL's ROE is +0.40%, compared to INCY's ROE of +0.30%. Regarding short-term risk, EXEL is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check INCY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while BNTX trades at $90.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas BNTX's P/E ratio is -19.61. In terms of profitability, EXEL's ROE is +0.40%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, EXEL is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BNTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while UTHR trades at $517.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas UTHR's P/E ratio is 19.10. In terms of profitability, EXEL's ROE is +0.40%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EXEL is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check UTHR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MRNA trades at $54.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MRNA's P/E ratio is -6.73. In terms of profitability, EXEL's ROE is +0.40%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, EXEL is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MRNA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while INSM trades at $98.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas INSM's P/E ratio is -17.15. In terms of profitability, EXEL's ROE is +0.40%, compared to INSM's ROE of -1.30%. Regarding short-term risk, EXEL is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check INSM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EXEL's ROE is +0.40%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, EXEL is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BGNE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EXEL's ROE is +0.40%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, EXEL is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check DNA-WT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas GMAB's P/E ratio is 20.77. In terms of profitability, EXEL's ROE is +0.40%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, EXEL is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check GMAB's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while NBIX trades at $166.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas NBIX's P/E ratio is 24.10. In terms of profitability, EXEL's ROE is +0.40%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, EXEL is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check NBIX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while JAZZ trades at $252.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, EXEL's ROE is +0.40%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, EXEL is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check JAZZ's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while BBIO trades at $80.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas BBIO's P/E ratio is -21.41. In terms of profitability, EXEL's ROE is +0.40%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, EXEL is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BBIO's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ASND trades at $243.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ASND's P/E ratio is -100.79. In terms of profitability, EXEL's ROE is +0.40%, compared to ASND's ROE of -56.42%. Regarding short-term risk, EXEL is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ASND's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EXEL's ROE is +0.40%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EXEL is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check KRTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ARWR trades at $84.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ARWR's P/E ratio is -39.37. In terms of profitability, EXEL's ROE is +0.40%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, EXEL is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ARWR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while BMRN trades at $60.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas BMRN's P/E ratio is 28.86. In terms of profitability, EXEL's ROE is +0.40%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, EXEL is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BMRN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while TECH trades at $72.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas TECH's P/E ratio is 37.16. In terms of profitability, EXEL's ROE is +0.40%, compared to TECH's ROE of +0.05%. Regarding short-term risk, EXEL is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check TECH's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RNAM's P/E ratio is -17.39. In terms of profitability, EXEL's ROE is +0.40%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, EXEL is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RNAM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while AXSM trades at $217.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas AXSM's P/E ratio is -56.92. In terms of profitability, EXEL's ROE is +0.40%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, EXEL is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check AXSM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MDGL trades at $467.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MDGL's P/E ratio is -36.51. In terms of profitability, EXEL's ROE is +0.40%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, EXEL is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MDGL's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while SMMT trades at $13.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas SMMT's P/E ratio is -8.14. In terms of profitability, EXEL's ROE is +0.40%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, EXEL is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check SMMT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while KRYS trades at $341.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas KRYS's P/E ratio is 45.60. In terms of profitability, EXEL's ROE is +0.40%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, EXEL is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check KRYS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while HALO trades at $82.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas HALO's P/E ratio is 17.87. In terms of profitability, EXEL's ROE is +0.40%, compared to HALO's ROE of +1.26%. Regarding short-term risk, EXEL is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check HALO's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CYTK trades at $77.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CYTK's P/E ratio is -13.23. In terms of profitability, EXEL's ROE is +0.40%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, EXEL is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CYTK's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EXEL's ROE is +0.40%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RXDX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ABVX trades at $124.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ABVX's P/E ratio is -65.48. In terms of profitability, EXEL's ROE is +0.40%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, EXEL is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ABVX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas NUVL's P/E ratio is -21.79. In terms of profitability, EXEL's ROE is +0.40%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, EXEL is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check NUVL's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CRNX trades at $83.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CRNX's P/E ratio is -16.28. In terms of profitability, EXEL's ROE is +0.40%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, EXEL is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CRNX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while PTGX trades at $136.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas PTGX's P/E ratio is -75.49. In terms of profitability, EXEL's ROE is +0.40%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, EXEL is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check PTGX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EXEL's ROE is +0.40%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, EXEL is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check IMGN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while IONS trades at $51.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas IONS's P/E ratio is -30.10. In terms of profitability, EXEL's ROE is +0.40%, compared to IONS's ROE of -1.11%. Regarding short-term risk, EXEL is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check IONS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while PRAX trades at $307.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas PRAX's P/E ratio is -23.02. In terms of profitability, EXEL's ROE is +0.40%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, EXEL is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check PRAX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while SYRE trades at $98.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas SYRE's P/E ratio is -47.27. In terms of profitability, EXEL's ROE is +0.40%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check SYRE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while KYMR trades at $103.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas KYMR's P/E ratio is -29.29. In terms of profitability, EXEL's ROE is +0.40%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, EXEL is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check KYMR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ALKS trades at $48.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ALKS's P/E ratio is 52.66. In terms of profitability, EXEL's ROE is +0.40%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, EXEL is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ALKS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas BPMC's P/E ratio is -51.58. In terms of profitability, EXEL's ROE is +0.40%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BPMC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while APGE trades at $134.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas APGE's P/E ratio is -30.97. In terms of profitability, EXEL's ROE is +0.40%, compared to APGE's ROE of -0.33%. Regarding short-term risk, EXEL is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check APGE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CERE's P/E ratio is -16.47. In terms of profitability, EXEL's ROE is +0.40%, compared to CERE's ROE of -0.72%. Regarding short-term risk, EXEL is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CERE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while TGTX trades at $52.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas TGTX's P/E ratio is 17.88. In terms of profitability, EXEL's ROE is +0.40%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, EXEL is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check TGTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while IMVT trades at $38.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas IMVT's P/E ratio is -14.46. In terms of profitability, EXEL's ROE is +0.40%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, EXEL is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check IMVT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while PCVX trades at $54.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas PCVX's P/E ratio is -7.86. In terms of profitability, EXEL's ROE is +0.40%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, EXEL is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check PCVX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while IBRX trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas IBRX's P/E ratio is -8.44. In terms of profitability, EXEL's ROE is +0.40%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, EXEL is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check IBRX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MTSR's P/E ratio is -23.58. In terms of profitability, EXEL's ROE is +0.40%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, EXEL is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MTSR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MRUS's P/E ratio is -17.05. In terms of profitability, EXEL's ROE is +0.40%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, EXEL is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MRUS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RYTM trades at $99.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RYTM's P/E ratio is -31.71. In terms of profitability, EXEL's ROE is +0.40%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, EXEL is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check RYTM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ACLX's P/E ratio is -28.27. In terms of profitability, EXEL's ROE is +0.40%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, EXEL is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ACLX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while COGT trades at $38.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas COGT's P/E ratio is -18.45. In terms of profitability, EXEL's ROE is +0.40%, compared to COGT's ROE of -0.83%. Regarding short-term risk, EXEL is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check COGT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RETA's P/E ratio is -66.29. In terms of profitability, EXEL's ROE is +0.40%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EXEL is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RETA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MIRM trades at $105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MIRM's P/E ratio is -7.78. In terms of profitability, EXEL's ROE is +0.40%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, EXEL is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MIRM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while BLTE trades at $158.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas BLTE's P/E ratio is -84.82. In terms of profitability, EXEL's ROE is +0.40%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, EXEL is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BLTE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ERAS trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ERAS's P/E ratio is -19.51. In terms of profitability, EXEL's ROE is +0.40%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, EXEL is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ERAS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CGON trades at $71.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CGON's P/E ratio is -30.55. In terms of profitability, EXEL's ROE is +0.40%, compared to CGON's ROE of -0.23%. Regarding short-term risk, EXEL is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CGON's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CNTA's P/E ratio is -22.63. In terms of profitability, EXEL's ROE is +0.40%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, EXEL is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CNTA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while XENE trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas XENE's P/E ratio is -13.33. In terms of profitability, EXEL's ROE is +0.40%, compared to XENE's ROE of -0.49%. Regarding short-term risk, EXEL is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check XENE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while LGND trades at $287.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas LGND's P/E ratio is 34.48. In terms of profitability, EXEL's ROE is +0.40%, compared to LGND's ROE of +0.16%. Regarding short-term risk, EXEL is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check LGND's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while SRRK trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas SRRK's P/E ratio is -13.17. In terms of profitability, EXEL's ROE is +0.40%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, EXEL is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check SRRK's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while PTCT trades at $68.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas PTCT's P/E ratio is -29.19. In terms of profitability, EXEL's ROE is +0.40%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, EXEL is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PTCT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CDTX's P/E ratio is -19.77. In terms of profitability, EXEL's ROE is +0.40%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, EXEL is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CDTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EXEL's ROE is +0.40%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EXEL is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ABCM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EXEL's ROE is +0.40%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EXEL is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ISEE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas APLS's P/E ratio is 38.35. In terms of profitability, EXEL's ROE is +0.40%, compared to APLS's ROE of +0.40%. Regarding short-term risk, EXEL is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check APLS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while TVTX trades at $55.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas TVTX's P/E ratio is -254.05. In terms of profitability, EXEL's ROE is +0.40%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, EXEL is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check TVTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas TERN's P/E ratio is -51.41. In terms of profitability, EXEL's ROE is +0.40%, compared to TERN's ROE of -0.20%. Regarding short-term risk, EXEL is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check TERN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while DFTX trades at $43.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas DFTX's P/E ratio is N/A. In terms of profitability, EXEL's ROE is +0.40%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, EXEL is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check DFTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while DYN trades at $25.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas DYN's P/E ratio is -7.82. In terms of profitability, EXEL's ROE is +0.40%, compared to DYN's ROE of -0.64%. Regarding short-term risk, EXEL is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check DYN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CRSP trades at $47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CRSP's P/E ratio is -9.39. In terms of profitability, EXEL's ROE is +0.40%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CRSP's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas FOLD's P/E ratio is -161.00. In terms of profitability, EXEL's ROE is +0.40%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, EXEL is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check FOLD's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas AKRO's P/E ratio is -14.57. In terms of profitability, EXEL's ROE is +0.40%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, EXEL is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check AKRO's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while DNTH trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas DNTH's P/E ratio is -25.89. In terms of profitability, EXEL's ROE is +0.40%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, EXEL is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check DNTH's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EXEL's ROE is +0.40%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, EXEL is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ALPN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ACAD trades at $25.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ACAD's P/E ratio is 12.68. In terms of profitability, EXEL's ROE is +0.40%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, EXEL is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ACAD's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CAI trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CAI's P/E ratio is -86.19. In terms of profitability, EXEL's ROE is +0.40%, compared to CAI's ROE of +0.06%. Regarding short-term risk, EXEL is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CAI's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MANE trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MANE's P/E ratio is -33.36. In terms of profitability, EXEL's ROE is +0.40%, compared to MANE's ROE of -0.84%. Regarding short-term risk, EXEL is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MANE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas OPT's P/E ratio is -1.52. In terms of profitability, EXEL's ROE is +0.40%, compared to OPT's ROE of +1.18%. Regarding short-term risk, EXEL is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check OPT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas PRTC's P/E ratio is -3.78. In terms of profitability, EXEL's ROE is +0.40%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, EXEL is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check PRTC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CELC trades at $86.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CELC's P/E ratio is -22.15. In terms of profitability, EXEL's ROE is +0.40%, compared to CELC's ROE of -2.45%. Regarding short-term risk, EXEL is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CELC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while EWTX trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas EWTX's P/E ratio is -23.15. In terms of profitability, EXEL's ROE is +0.40%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, EXEL is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check EWTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EXEL's ROE is +0.40%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EXEL is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MRTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ELVN trades at $54.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ELVN's P/E ratio is -32.82. In terms of profitability, EXEL's ROE is +0.40%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, EXEL is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ELVN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CPRX's P/E ratio is 12.30. In terms of profitability, EXEL's ROE is +0.40%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, EXEL is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CPRX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EXEL's ROE is +0.40%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EXEL is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RYZB's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EXEL's ROE is +0.40%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EXEL is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CBAY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while VKTX trades at $31.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas VKTX's P/E ratio is -7.67. In terms of profitability, EXEL's ROE is +0.40%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, EXEL is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check VKTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while DNLI trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas DNLI's P/E ratio is -7.99. In terms of profitability, EXEL's ROE is +0.40%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, EXEL is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check DNLI's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ORKA trades at $96.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ORKA's P/E ratio is -49.75. In terms of profitability, EXEL's ROE is +0.40%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, EXEL is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ORKA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ADPT trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ADPT's P/E ratio is -41.80. In terms of profitability, EXEL's ROE is +0.40%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, EXEL is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ADPT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ALMS trades at $28.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ALMS's P/E ratio is -7.39. In terms of profitability, EXEL's ROE is +0.40%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, EXEL is more volatile compared to ALMS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ALMS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while RCUS trades at $28.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas RCUS's P/E ratio is -8.66. In terms of profitability, EXEL's ROE is +0.40%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, EXEL is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RCUS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas SWTX's P/E ratio is -13.78. In terms of profitability, EXEL's ROE is +0.40%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, EXEL is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check SWTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 13.3B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, EXEL is priced at $53.03 on the NASDAQ, while ARQT trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 15.88, whereas ARQT's P/E ratio is -933.00. In terms of profitability, EXEL's ROE is +0.40%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, EXEL is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ARQT's competition here